Epcoritamab + Rituximab + Lenalidomide
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma (FL)
Conditions
Follicular Lymphoma (FL)
Trial Timeline
Sep 20, 2022 → Dec 1, 2029
NCT ID
NCT05409066About Epcoritamab + Rituximab + Lenalidomide
Epcoritamab + Rituximab + Lenalidomide is a phase 3 stage product being developed by AbbVie for Follicular Lymphoma (FL). The current trial status is active. This product is registered under clinical trial identifier NCT05409066. Target conditions include Follicular Lymphoma (FL).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05409066 | Phase 3 | Active |
Competing Products
20 competing products in Follicular Lymphoma (FL)